Clinical Trial

A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of praliciguat in adults with biopsy-confirmed focal segmental glomerulosclerosis (FSGS). Participants will be randomized 1:1 to receive praliciguat or placebo for initial 24 week treatment period. Following this double-blind period, all participants will receive praliciguat in an open-label extension for an additional 24 weeks.
Protocol Amendment History 2 changes
notable Trial sites expanded: 14 -> 23 locations 2026-07-14
notable Trial sites expanded: 10 -> 14 locations 2026-06-06
Trial Details
NCT Number NCT07268638
Lead Sponsor Akebia Therapeutics
Conditions Focal Segmental Glomerulosclerosis
Enrollment 60 participants
Start Date 2025-12-03
Primary Completion 2027-06 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-13